VantAI pairs bleeding-edge machine learning techniques with deep systems biology expertise to build computational models that uncover hidden relationships between molecules, targets, and diseases. These models power a best-in-class solution that identifies and generates new molecular entities for targets of interest, repurposes existing molecules at any stage of development, uncovers accurate ADME and toxicological insights, and predicts adverse events likely to influence trial success from deep analysis of systems-based pharmacogenomics. VantAI's in silico platform specializes in modelling complex protein-protein interactions, powering the discovery of biologics and protein degraders in addition to small-molecule drugs. It has helped leading biopharma partners launch new development programs--or revitalize old ones--at a fraction of the time and cost of traditional methods. For more information, please visit http://www.vant.ai.
| Website | http://www.vant.ai |
| Revenue | $5.6 million |
| Employees | 65 (55 on RocketReach) |
| Founded | 2019 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+18 more
(view full list)
|
| Industry | Biotechnology |
| Keywords | Data Driven Drug Discovery, Machine Learning Models, Advanced Analytics Platform, Computational Biology, Drug Discovery Platform, Therapeutics, Ai Drug Development, Molecular Modeling Software, Biotechnology Ai, Precision Medicine, Target Identification, Disease Modeling, Biomarker Discovery, Pharmaceutical Ai, Cheminformatics, Molecular Dynamics |
| Competitors | Amazon, Microsoft, IBM, Salesforce, NVIDIA, OpenAI, C3 AI, H2O.ai, DataRobot, AI Community +45 more (view full list) |
Looking for a particular VantAI employee's phone or email?
The VantAI annual revenue was $5.6 million in 2026.
Si-Han Chen is the Senior Director, Head of Computational Chemistry of VantAI.
55 people are employed at VantAI.
VantAI is based in New York, New York.